Kairos Pharma, Ltd.
KAPA · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $40 | $40 | $40 | $40 |
| Gross Profit | -$40 | -$40 | -$40 | -$40 |
| % Margin | – | – | – | – |
| R&D Expenses | $608 | $496 | $493 | $172 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $717 | $842 | $733 | $1,234 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,325 | $1,338 | $1,226 | $1,406 |
| Operating Income | -$1,365 | -$1,378 | -$1,266 | -$1,446 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$33 | -$44 | $4 | $466 |
| Pre-Tax Income | -$1,398 | -$1,422 | -$1,262 | -$980 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,398 | -$1,422 | -$1,262 | -$980 |
| % Margin | – | – | – | – |
| EPS | -0.07 | -0.083 | -0.08 | -0.071 |
| % Growth | 15.3% | -3.9% | -11.5% | – |
| EPS Diluted | -0.07 | -0.083 | -0.08 | -0.071 |
| Weighted Avg Shares Out | 20,206 | 17,213 | 15,875 | 13,737 |
| Weighted Avg Shares Out Dil | 20,206 | 17,213 | 15,875 | 13,737 |
| Supplemental Information | – | – | – | – |
| Interest Income | $37 | $34 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $133 |
| Depreciation & Amortization | $40 | $40 | $40 | $40 |
| EBITDA | -$1,358 | -$1,382 | -$1,222 | -$807 |
| % Margin | – | – | – | – |